pharmaceutical investing Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
pharmaceutical investing Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine
Shire Reports Record Full-year Revenue and Strong Double Digit Growth in Non GAAP Diluted Earnings per ADS
Westport to Issue Q2 2025 Financial Results on August 11, 2025 and Provides an Update on the Divestment of the Light-Duty Segment
Blue Lagoon Resources Added to CSE25 Index - Recognized Among 25 Largest Companies on the Canadian Securities Exchange
